| Drug Name |
Rifabutin |
| Drug ID |
BADD_D01935 |
| Description |
A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. |
| Indications and Usage |
Rifabutin is an antibiotic that inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme. It is bactericidal and has a very broad spectrum of activity against most gram-positive and gram-negative organisms (including Pseudomonas aeruginosa) and specifically Mycobacterium tuberculosis. Because of rapid emergence of resistant bacteria, use is restricted to treatment of mycobacterial infections and a few other indications. Rifabutin is well absorbed when taken orally and is distributed widely in body tissues and fluids, including the CSF. It is metabolized in the liver and eliminated in bile and, to a much lesser extent, in urine, but dose adjustments are unnecessary with renal insufficiency. |
| Marketing Status |
Prescription |
| ATC Code |
J04AB04 |
| DrugBank ID |
DB00615
|
| KEGG ID |
D00424
|
| MeSH ID |
D017828
|
| PubChem ID |
135398743
|
| TTD Drug ID |
D05CHI
|
| NDC Product Code |
68180-285; 70954-041; 59762-1350; 0013-5301; 73309-108 |
| Synonyms |
Rifabutin | Rifabutine | Ansamycin | Mycobutin | Ansatipine | LM-427 | LM 427 | LM427 | Alfacid | Ansatipin |
